Zepto was honored to participate in the J.P. Morgan 2025 Healthcare Conference, a global gathering of healthcare investors, innovators, and executives.
After presenting our pitch, Zepto had the opportunity to engage with leading investors, strategic partners, and fellow innovators who share our commitment to advancing healthcare through transformative technologies. The interest we received underscore the urgent need for faster, more accurate infectious disease diagnostics. As we continue to build momentum, we remain focused on accelerating development, expanding clinical collaborations, and ultimately improving outcomes for patients facing life-threatening fungal infections.
Thank you to the organizers of the J.P. Morgan Healthcare Conference and the broader community for their support. We look forward to what’s ahead.
About Zepto Life Technology
Zepto Life Technology is a molecular diagnostics company developing targeted liquid biopsy diagnostics for infectious diseases using proprietary Giant Magnetoresistance (GMR) biosensor technology. The company’s Zepto MDx platform is designed to enable highly sensitive detection and identification of pathogens directly from blood, beginning with invasive fungal infections.